Company intelligence / Profile preview

Organeva

San Diego, California, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Organovo has demonstrated preclinical efficacy with its engineered human tissues and received orphan drug designation from the FDA for its lead liver tissue program targeting alpha‑1 antitrypsin deficiency. Its ExVive Human Liver and Kidney Tissues are commercially available for preclinical drug testing. The company’s first therapeutic IND was targeted for submission in 2020; current clinical results are not publicly detailed as of June 2025.

Therapeutic areas: GastroenterologyRare Diseases
Modalities: Cell therapy (3D bioprinted tissue)Biologic (engineered tissues)
Industry: Biotech

Partnerships

L’Oreal – skin tissue engineering/cosmetic testing partnershipMultiple top global pharmaceutical companies – early access/collaborative research on kidney models

Beyond the preview

Go deeper on Organeva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Organeva.

Explore the full profile